Compare SaaS Products
Compare up to 4 software products side by side. Find the best solution for your business.
Add Products to Compare
2 of 4 products selected
| Feature | ||
|---|---|---|
| Rating |
4.1
|
4.0
|
| Reviews | 15 | 9 |
| Category | Biotech | Biotech |
| Description |
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma. |
We are building the next generation of deep-learning models for enzyme design to slash the cost of chemical manufacturing. The $6 trillion chemical industry is flawed: It produces 20% of industrial greenhouse gases, and is responsible for 15% of global energy usage. Enzymes offer a far more sustainable alternative to chemical synthesis and have already revolutionised how a select few chemicals are produced. The problem is each enzyme takes years of trial and error to develop. Our enzyme models learn the principles of catalysis, allowing us to design enzymes for each reaction, in days not years. We currently have $4.3M of LOIs and have completed our first $20k contract. |
| Website | http://www.erisbio.com | https://www.ligo.bio |
| Positives |
"Well-designed interface and powerful features."
Amiya Marquardt - 5/5
|
"Fast, reliable, and constantly improving. Great product!"
Reba Mueller - 5/5
|
| Negatives |
"Customer support was slow to respond to our issues."
Mr. Cleveland Pouros - 1/5
|
"Integration was difficult and documentation was unclear."
Newton Moore - 1/5
|
| Details | View Full Review → | View Full Review → |
